Limited data exist regarding the incidence and factors associated with outcome of invasive Pseudomonal infections in hematopoietic cell transplant (HCT). A retrospective analysis of cases of invasive Pseudomonas aeruginosa infection and factors associated with outcome was performed. P. aeruginosa invasive infection occurred in 95 of 5772 patients (1.65%) a median of 63 days after HCT (range 5-1435). Only 28% of infections occurred during periods of neutropenia (absolute neutrophil counto500 cells/mm 3 ). Infection-attributable mortality during the initial episode of infection was 35.8%. Factors associated with initial mortality included the presence of a copathogen and high-dose steroid use. Ten (16.4%) of those who survived the initial infection experienced a recurrence of P. aeruginosa infection at a median of 9 days (range 3-17) after stopping antibiotics and 60% of those died as a result of recurrent infection a median of 1 day (range 1-7) after onset of recurrence. Grade 3-4 graft-versus-host disease was associated with a higher risk of recurrent infection. The risk of recurrence was not influenced by the presence of copathogens. Thus, invasive P. aeruginosa infections are associated with high recurrence rates and mortality in this immunocompromised population. Aggressive attempts to reduce immunosuppression and to treat copathogens may help during the initial infection.
Introduction
In contrast to viral and fungal infections, bacterial infections in patients undergoing hematopoietic stem cell transplantation (HCT) have received comparatively little attention in the literature over the past decade. However, bacterial infections remain significant causes of morbidity and mortality in this population. [1] [2] [3] Many factors predispose HCT recipients to invasive bacterial infections, including the disruption of mucosal barriers as a result of mucositis, graft-versus-host disease (GVHD), 4 ,5 the use of indwelling central venous catheters, 6 the use of steroids for GVHD, 7 impaired humoral immunity 7, 8 and neutropenia. 9, 10 The use of prophylactic antibiotics, especially during periods of neutropenia and chronic GVHD, as well as shorter time to engraftment with the use of peripheral stem cells, has decreased the incidence of gram-negative bacteremia from rates of 30-40% in the 1980s to rates of approximately 10-20% more recently. 2, [11] [12] [13] [14] Pseudomonas aeruginosa accounts for a minority of bacteremic episodes in patients undergoing HCT 3, 6, 15 but is the most common pathogen isolated in bacterial pneumonia occurring before day 100 post-transplant. 4 Owing to antibiotic resistance, it can be difficult to treat 16 and in addition, the colonization of sites such as the lung and gastrointestinal tract may lead to relapse of infection once antibiotics are discontinued. 17 These factors result in the tendency to use synergistic antibiotic combinations for prolonged periods of time to treat this organism. 16 Few published studies have focused specifically on the outcome of P. aeruginosa infections in the HCT population since the advent of potent anti-Pseudomonal antibiotics. The aim of the present study was to analyze the characteristics of invasive P. aeruginosa infection after HCT and to determine the factors associated with mortality and recurrent infection.
Materials and methods

Case finding and microbiological data
The study population consisted of 5772 patients who underwent first or second bone marrow or peripheral blood stem cell transplantation at the Fred Hutchinson Cancer Research Center (FHCRC) in Seattle, Washington between January 1990 and March 2001. Microbiological data for these patients were stored electronically in a database maintained in the FHCRC computer system. This database was searched for all P. aeruginosa isolates obtained between 1990 and 2001, as well as the site of culture, which was limited to sputum, bronchoalveolar lavage (BAL) fluid, lung biopsy and blood culture. Susceptibility data for these isolates were reviewed via stored records when available. The study was approved by the Institutional Review Board at the FHCRC.
Case definitions and clinical characteristics
Patient care charts, progress notes, laboratory values and medication lists are stored electronically in the FHCRC computer system and were reviewed for each patient identified by the above microbiological queries. Patients were categorized as having bacteremia, pneumonia or bacteremic pneumonia based on the hypothesis that these various clinical manifestations of infection would be associated with different clinical outcomes. A single positive blood culture was considered significant and that patient included in the study. Pneumonia was defined as isolation of an organism from sputum, BAL fluid or lung biopsy tissue along with clinical evidence of pneumonia (infiltrates on radiographs, hypoxia, with or without fever) as determined after chart review. Cases in which a patient had both bacteremia and pneumonia with the same organism isolated from blood and pulmonary specimens within 7 days of each other were grouped as 'bacteremic pneumonia'. Patient charts were reviewed to determine antibiotic usage, clinical course, presence or absence of neutropenia (defined by absolute neutrophil count (ANC) of o500 cells/mm 3 ) at the time of infection, GVHD at the time of infection, IgG levels (normal 670-1700) within a period of 7 days before or after the onset of infection, steroid use at the time of infection, and concomitant infection with other significant organisms. 7 Mortality was considered to be attributable to the organism in question if the patient expired within 14 days of the initial culture and the circumstances surrounding the patients' death were consistent with a progressive infectious process (evidence of sepsis, fever, progressive pneumonia and/or histopathological evidence of end-organ invasive P. aeruginosa) after chart review and review of autopsy reports.
Antibiotic prophylaxis and treatment guidelines
During the time period studied, from 1990 to 2001, guidelines set forth by the Program in Infectious Diseases and Oncology/Transplantation at the FHCRC were used to govern the approach to the patient with suspected and documented bacterial infection. With rare exception, all patients were treated in a separate ward dedicated to the care of HCT recipients. Prophylactic systemic antibiotics active against gram-negative bacilli (ceftazidime) were started once the ANC dropped below 500/mm 3 , regardless of whether fever or other clinical manifestations of infection were present. At the onset of febrile neutropenia, if an organism other than a gram-negative rod was suspected, a second agent such as a fluoroquinolone or vancomycin was empirically recommended. An antifungal agent (amphotericin B or liposomal amphotericin B) was added for cases of persistent (typically472 h) febrile neutropenia or suspected fungal infection. Owing to the high-risk nature of these patients, empiric antibiotic treatment generally was continued until neutropenia resolved, regardless of the resolution of fevers. 18, 19 Bacteremia without a focus was treated with intravenous antibiotics, the nature of the regimen being at the discretion of the treating physicians. All patients with suspected infection had blood cultures drawn on at least one occasion during the course of their treatment. In accordance with FHCRC policy, patients on steroid therapy had surveillance blood cultures drawn two or three times per week when hospitalized and twice weekly when followed in the outpatient department, even in the absence of any manifestations of active infection (i.e. fever).
Recurrent infection
Recurrent bacteremia was defined as isolation of P. aeruginosa after initial clearing of blood cultures for at least 7 days with evidence of clinical improvement as determined by chart review. Recurrent pneumonia was defined as initial clinical improvement after initiation of antibiotics (i.e. resolving infiltrate, defervescence, reduced oxygen requirements) followed by isolation of the same organism from BAL or biopsy material along with clinical deterioration. Molecular analysis of initial and recurrent isolates (when available) was performed using pulsed-field gel electrophoresis (PFGE) as described previously. 20 PFGE patterns were reviewed by two independent reviewers and interpreted as described previously. 21 
Data analysis
Summary statistics including frequency counts and percentages for categorical variables and median and range for continuous variables were calculated. Comparisons from 2 Â 2 and 2 Â 3 tables were made using w 2 and Fisher's exact tests, as appropriate. Survival after diagnosis of invasive infection was analyzed using the Kaplan-Meier method. Multivariable analyses were carried out by logistic regression. The impact of co-pathogens on initial mortality and recurrence was analyzed statistically; we also repeated the entire analysis in patients without copathogens.
Results
Patient characteristics and incidence P. aeruginosa infection was documented in 95 patients that met our case definition: 74 cases in 3601 patients undergoing allogeneic transplantation (incidence 2%) and 21 in 2171 undergoing autologous transplantation (incidence 1%) during the study period (overall incidence of 1.65%). Patient characteristics are seen in Table 1 . Infection occurred at a median of 63 days after transplantation (range 5-1435); 77.9% of cases occurred in the first 3 months following transplantation. Sixty-seven patients (70.5%) had bacteremia alone, 16 (16.8%) had pneumonia, and 12 (12.6%) had bacteremic pneumonia. Twenty-seven (28.4%) patients were neutropenic at the time of diagnosis: 19 patients had ANCs between 100 and 500/mm 3 and eight had ANCs o100/mm 3 . Sixty-eight patients were experiencing grade 2 or greater GVHD and 66 patients were on X1 mg/kg/day of steroids at the time of diagnosis. Fortynine patients had invasive Pseudomonas infection without copathogens. The underlying characteristics of these patients were not different from the entire cohort (data not shown).
Initial mortality
Overall, 34 (35.8%) patients died within 14 days of the initial episode of infection. In a univariate analysis, individual factors associated with death from P. aeruginosa infection during the initial episode of infection were the presence of a copathogen and the use of high-dose steroids (X1 mg/kg/day) ( Table 2 and Figure 1 ). The disease manifestation (bacteremia vs pneumonia vs bacteremic pneumonia), hypogammaglobulinemia, neutropenia and time to onset of infection from transplantation were not significantly associated with higher initial mortality when analyzed alone (Table 2) . Only the presence of a copathogen remained a statistically significant predictor of mortality when analyzed in a bivariate model with high-dose (X1 mg/kg/day) steroid use (odds ratio (OR) 5.0, 95% confidence interval (CI) 2.0-13, P ¼ 0.0004 for the presence of a copathogen; OR 2.5, 95% CI 0.85-7.4, P ¼ 0.086 for high-dose steroid use). Notably, combinations of factors frequently encountered in this patient population, such as high-dose steroid use along with the presence of a copathogen, or neutropenia along with a copathogen, were also significant predictors of infection-attributable mortality (Table 2) . 
2% of those who died during the initial infection (P ¼ NS).
Recurrent infection
Of the 61 patients who survived the initial infection, 10 (16.4%) experienced a recurrence of infection. The median number of days to recurrence after stopping antibiotics was 9 days (range 3-17). Infection-attributable mortality after recurrence of infection was 60% (6 of 10). Among the six patients whose death was considered to be due to the recurrent infection, the median number of days to death after recurrence was 1 day (range 1-7). The clinical presentation in the patients with fulminant death was septic shock. Recurrent infection was significantly associated with grade 3-4 GVHD compared with grades 0-2 (35 vs 7.3%, P ¼ 0.01) ( Table 3 ). There was a trend towards increased risk of recurrence among those who received o14 days of antibiotics to treat the initial infection compared with those who received at least 14 days, although this did not reach statistical significance (31.6 vs 10%, P ¼ 0.06). Neutropenia (ANCo500/mm 3 ), hypogammaglobulinemia and steroid use (41 mg/kg) were not significantly associated with recurrent infection.
A subset analysis of patients who had recurrent invasive Pseudomonas infection without copathogens (N ¼ 6) confirmed grade 3-4 GVHD (P ¼ 0.03) as risk factor for recurrence. Three of the six patients without copathogens died due to Pseudomonas infection during the recurrent episode (within 7 days of diagnosis).
Two cases (of 10) of P. aeruginosa recurrence had isolates from both the initial infection and the recurrence available for PFGE analysis. Both cases yielded identical restriction patterns, indicating relapse of infection with the initial infecting isolate (Figure 2 ).
Antibiotic susceptibility patterns in recurrent infection
Antibiotic susceptibility data were available for eight of the 10 (80%) cases of recurrence from our cohort. Antibiotic susceptibility patterns were the same between the initial isolate and the recurrent isolate in five cases. In two cases, the susceptibility changes involved a change from 'sensitive' Table 3 Frequency of factors associated with recurrent (n ¼ 10) and non-recurrent (n ¼ 51) pseudomonas aeruginosa infection among those surviving the initial infection Table 2. to 'resistant' to an antibiotic that had been used for treatment of the initial infection in these patients: imipenem in case 1 and ceftazidime in case 2 (Table 4) . Notably, both of these antibiotics were used along with an aminoglycoside to treat the initial infection; both patients died. Subtle changes in susceptibility patterns developed to antibiotics that had not been used to treat the initial infection in case 3 (Table 4 ). However, the PFGE patterns of the initial and recurrent isolate in this case were identical (Figure 2, lanes  a1 and a2) . Therefore, it appears that the susceptibility pattern of the recurrent organism cannot necessarily be predicted based on past antibiotic exposure.
Discussion
We found that invasive infection with P. aeruginosa occurred relatively infrequently after HCT but was associated with significant mortality, frequent recurrence and very high mortality during recurrent infection.
Mortality was associated with the administration of highdose steroids, the presence of a copathogen, as well as the combined presence of a copathogen along with high-dose steroids or neutropenia. Only grade 3-4 GVHD was associated with recurrent infection, although a trend was observed for those who received shorter course of antibiotics to treat the initial infection.
The mortality attributable to P. aeruginosa infection in our patient population was similar to that published in two recent analyses of bacteremia after HCT 15, 22 and was considerably greater than in the general hospital population, where the mortality rate is roughly 7%. 17, 22, 23 Previous studies have determined the contribution of gut GVHD and systemic steroid therapy towards the development in gram-negative bacteremia, 6, 22 whereas the results of our study demonstrate that such immunomodulatory factors also are important determinants of outcome. Additionally, an analysis comparing bacterial infections after myeloablative transplant and nonmyeloablative transplant found significantly fewer bacterial infections and lower infectionrelated mortality after nonmyeloablative transplantation, possibly due in part to the lower incidence and shorter duration of neutropenia as well as less conditioning regimen-related toxicity. 24 Likewise, the recurrence rate observed in our study appeared to be higher than that in the general hospitalized population (16.4 vs 6-10%) and, consistent with its role in primary infection, 6 ,22 the presence of GVHD was the primary risk factor contributing to recurrence.
We did not find a statistically significant difference in the antibiotic usage between those who experienced recurrent infection and those who did not, although we did observe a trend towards a reduced risk of recurrence with longer courses of antibiotics during the primary infection. Others have noted significantly shorter duration of antibiotic therapy in patients who experience a recurrence of bacteremia compared with those do not. 17 In those studies, patients who experienced recurrent infection tended to be immunosuppressed, and it was thought that these patients Table 4 Cases of organisms with different susceptibility patterns in recurrent infection compared with the initial isolate may require a longer duration of antibiotic therapy to eradicate the primary site of infection. 17 Although only two pairs of isolates from recurrent episodes of infection were available for PFGE testing, the fact that both cases that were analyzed yielded identical restriction patterns suggests that cases of recurrent infection may in fact be due to a recurrence with the initial organism; this finding is in agreement with a previously published analysis of recurrent bacteremia. 21 Thus, recurrent infection may be due to failure to eradicate the organism during initial antibiotic treatment, subsequently leading to relapse once antibiotics are discontinued. Given the extremely high mortality rate after relapse, certain measures should be taken to lessen this risk. Thoroughly searching for and removing any nidus of infection (e.g. an infected central venous catheter) is perhaps the most important aspect of preventing recurrence of infection. Treating patients with a minimum of a 2-week course of antibiotics also should be considered in the presence of identifiable risk factors for mortality and relapse of infection, such as severe GVHD, the use of high-dose steroids and copathogens. Reducing the dose of steroids may only be possible in the minority of patients (e.g. with isolated mild skin GVHD) and may aggravate bacterial invasion in the case of gut GVHD.
It is important to recognize that the emergence of a pathogen resistant to one of the antibiotics used to treat the initial infection was seen infrequently, consistent with previous studies. 17, 21 Although these results suggest that recurrent infection with the same organism need not necessarily prompt a change in empiric antibiotic coverage, the choice of empiric antibiotics during a case of suspected recurrent Pseudomonal infection, or documented infection before susceptibility data, should, of course, be made based on the institutional resistance patterns and the clinical scenario at presentation.
The important strengths of our study include the use of a relatively large patient cohort that received fairly uniform diagnostic evaluation and antimicrobial therapy during the time period of this study. Therefore, we do not believe that our results are significantly affected by changes in clinical care over the time period of our study. The major limitations of this study are the retrospective, nonrandomized nature of the study and lack of controls. Additionally, owing to the retrospective nature of the study, aggressive searches for a nidus of recurrent infection (i.e. infected central venous catheter, gastrointestinal genitourinary tract or pulmonary sources) were either not carried out systematically or could not be verified for all patients. Finally, assessing the mortality directly attributable to P. aeruginosa infection is made difficult by the presence of copathogens in many cases. We chose to include these patients in the study but analyzed the data with and without copathogens. Our data suggest that, although copathogens are an important factor in initial mortality, they do not contribute to recurrence of P. aeruginosa infection. Additionally, the majority of these patients died within 1 week of recurrence, a temporal association indicating P. aeruginosa as the primary cause of death.
In conclusion, this study found a high initial mortality associated with invasive P. aeruginosa after HCT. A novel and clinically important finding is the risk of disease recurrence in patients with severe immunosuppression such as grade 3-4 GVHD; these patients may benefit from longer courses of antibiotic therapy, and physicians should be vigilant for evidence of recurrent infection once antibiotics are discontinued. A prospective randomized trial designed to assess these interventions is needed. However, given the fairly low frequency of the event, a trial of this nature would be difficult to conduct. Thus, aggressive management of the initial episode of infection aimed not only at antibiotic therapy but also emphasizing the treatment of copathogens and the correction of host factors whenever possible is recommended.
